Safety assessment based on reports of adverse events and clinical laboratory tests as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Up to 30 days after the last dose of study medication [clinicaltrials_resource:a1b9a0e05229fb88fb021e151eba4a92]
Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Safety assessment based on reports of adverse events and clinical laboratory tests as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Up to 30 days after the last dose of study medication [clinicaltrials_resource:a1b9a0e05229fb88fb021e151eba4a92]
Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks
Bio2RDF identifier
a1b9a0e05229fb88fb021e151eba4a92
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a1b9a0e05229fb88fb021e151eba4a92
measure [clinicaltrials_vocabulary:measure]
Safety assessment based on rep ...... ria for Adverse Events (CTCAE)
time frame [clinicaltrials_vocabulary:time-frame]
Up to 30 days after the last dose of study medication
description
Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks
identifier
clinicaltrials_resource:a1b9a0e05229fb88fb021e151eba4a92
title
Safety assessment based on rep ...... last dose of study medication
@en
type
label
Safety assessment based on rep ...... 9a0e05229fb88fb021e151eba4a92]
@en